Results 91 to 100 of about 13,427 (242)

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

Allergen-specific immunotherapy: State of the art

Global Pediatrics
Allergen-specific immunotherapy (AIT) was born in 1911 and great progress has been made over the last 110 years, from the invention of subcutaneous and sublingual administration to new strategies.
Roberto Bernardini, Diego G. Peroni, Pasquale Comberiati, Serena Gracci   +3 more
doaj   +1 more source

Allergen-specific immunotherapy and evidence: A European regulatory perspective. [PDF]

Allergol Select, 2023
Bartel D, Bonertz A, Hartenstein D, Kaul S, Lauer I, Reeb C, Rösner-Friese K, Sliva K, Zimmer J, Vieths S, Mahler V.   +10 more
europepmc   +1 more source

Comorbid Chronic Rhinosinusitis and Asthma: Shared Risk Factors and Treatment Implications—An EAACI Task Force Report

Allergy, EarlyView.
ABSTRACT Chronic rhinosinusitis (CRS) and asthma are prevalent conditions that often coexist. These diseases share common inflammatory mechanisms, such as T‐helper cell 2 (T2)‐high inflammation, driven by interleukin (IL)‐4, IL‐5, and IL‐13 cytokines.
Sanna Toppila‐Salmi, Sietze Reitsma, Valérie Hox, Simon Gane, Philippe Gevaert, Juan Maza‐Solano, Alma Helevä, Ida Sulku, Kaisa Santala, Iiris Kangasniemi, Ludger Klimek, Adam Chaker, Aspasia Karavelia, Michael Rudenko, Oliver Pfaar, Laura Van Gerven, Shaari Ariana, Michele Schiappoli, Marie Lundberg, Jan Hagemann, Ibon Eguíluz‐Gracia, Andre Moreira   +21 more
wiley   +1 more source

A Review of Allergy and Allergen Specific Immunotherapy

Iranian Journal of Allergy, Asthma and Immunology, 2011
Since 20th  century, when allergy was defined, an ongoing attempt for discovering the mechanisms underlying it and its treatment began. Defining allergens as well as cells such as regulatory T-cells and characterizing the antibodies involved in the ...
Katayoon Bidad, Mohammad Hossein Nicknam, Reza Farid   +2 more
doaj  

A One‐Strength Dose Escalation Regimen for Birch Pollen SCIT Is Safe and Tolerable in Children, Adolescents, and Adults

Allergy, EarlyView.
This study evaluated safety and tolerability of birch pollen SCIT during dose escalation with a new One‐Strength regimen (3 injections, Strength B) compared to the Standard regimen (7 injections, Strengths A and B) in patients aged 5–65 years. Safety and tolerability were comparable between the two regimens in adults, adolescents, and adolescents, as ...
Marek Jutel, Ludger Klimek, Michael Gerstlauer, Dana Troyke, Kristina Duwensee, Christian Vogelberg   +5 more
wiley   +1 more source

Codfish Oral Immunotherapy in Children Aged 2–10: Randomized Placebo‐Controlled Study

Allergy, EarlyView.
Codfish OIT significantly increased desensitization in children with fish allergy (43% vs. 11% placebo, p = 0.003), with 69% achieving 10‐fold threshold increases versus 26% in placebo (p = 0.0003). Sustained unresponsiveness remained limited (23% vs. 9%, p = 0.332). Treatment demonstrated acceptable safety with predominantly mild reactions and reduced
Agnes Sze‐yin Leung, Yanjun Gu, Ann Wing‐shan Au, Rosetta Tsz‐ching Leung, Vanessa Hiu‐tung Tang, Kin Yi Fung, Janice Min Li, Christine Yee‐yan Wai, Ting Fan Leung, Gary Wing‐kin Wong   +9 more
wiley   +1 more source

Requirements for acquiring a high-quality house dust mite extract for allergen immunotherapy

Drug Design, Development and Therapy, 2012
Franco Frati,1 Cristoforo Incorvaia,2 Marie David,3 Silvia Scurati,3 Simona Seta,4 Guglielmo Padua,4 Eleonora Cattaneo,1 Carlo Cavaliere,5 Alessia Di Rienzo,6 Ilaria Dell'Albani,1 Paola Puccinelli11Medical and Scientific and Regulatory Department,
Frati F, Incorvaia C, David M, Scurati S, Seta S, Padua G, Cattaneo E, Cavaliere C, Di Rienzo A, Dell'Albani I, Puccinelli P   +10 more
doaj  

Circulating Type 2 Memory B Cell Frequency Is a Biomarker for Allergen Immunotherapy Efficacy in Patients With Allergic Rhinitis

Allergy, EarlyView.
Yue Ma, Shuying Li, Lei Ye, Lin Qiu, Jiayu Wu, Jiaying Li, Xian Feng, Wei Qian, Xiangping Yang, Huabin Li, Hongfei Lou   +10 more
wiley   +1 more source

Patient‐Perceived Benefits of Named‐Patient Product Sublingual Immunotherapy in Allergic Rhinitis and Asthma: Primary Results From the ERAPP Real‐World Cohort Study

Allergy, EarlyView.
Evaluation en vie Réelle de l'Allergo‐Prescription en Pratique (ERAPP) is a large, prospective, real‐world cohort of children and adults initiating named‐patient product sublingual immunotherapy (NPP‐SLIT) in France. More than 80% of patients reported a clinically meaningful, expectation‐anchored benefit (Patient Benefit Index ≥ 1) at 12–15 months. The
Davide Caimmi, Abdelilah Abouelfath, Régis Lassalle, Séverine Lignot‐Maleyran, Emmanuelle Bignon, Patrick Blin, Evangéline Clark, Julien Cottet, Laure Carcaillon‐Bentata, Pascal Demoly   +9 more
wiley   +1 more source